---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ESK-001-023"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: ESK-001-023. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 12 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence/esk-001-023"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ESK-001-023

<a id="heading-3.1.11"></a>

## 3.1.11 ESK-001-023

<a id="heading-3.1.11.1"></a>

### 3.1.11.1 Objective

<a id="topic-3.1.11.1-1"></a>

#### Brief summary in the ClinicalTrials.gov record

> “This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe renal impairment.”

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="heading-3.1.11.2"></a>

### 3.1.11.2 Location and Study Date

<a id="topic-3.1.11.2-1"></a>

#### Study start and completion dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2025-04-23”
> “Primary Completion (Actual) 2025-08-01”
> “Study Completion (Actual) 2025-08-01”
> “First Posted 2025-05-08”

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="topic-3.1.11.2-2"></a>

#### Start and completion dates estimated at registration, April 2025, superseded in December 2025

> “Study Start 2025-05-09 [Estimated]”
> “Primary Completion 2025-12 [Estimated]”
> “Study Completion 2025-12 [Estimated]”

Source: [ClinicalTrials.gov NCT06962774 version 1](https://clinicaltrials.gov/study/NCT06962774?tab=history&a=1)

<a id="topic-3.1.11.2-3"></a>

#### Sites in Florida in the ClinicalTrials.gov record

> “This study has 4 locations”

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

| Site | Quoted record |
| --- | --- |
| Florida | “Miami, Florida, United States, 33147” |
| Florida | “Miami Lakes, Florida, United States, 33014” |
| Florida | “Miami Lakes, Florida, United States, 33016” |
| Florida | “Orlando, Florida, United States, 32809” |

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="topic-3.1.11.2-4"></a>

#### Recruitment and results status in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2025-12-10” |

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="heading-3.1.11.3"></a>

### 3.1.11.3 Study Design

<a id="topic-3.1.11.3-1"></a>

#### Official title and design details in the ClinicalTrials.gov record

> “A Phase 1, Open-label, Single-dose Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of ESK-001”

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

| Field | Quoted record |
| --- | --- |
| Other study ID numbers | “ESK-001-023” |
| Conditions | “Renal Impairment” |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Single (Participant)” |

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="heading-3.1.11.4"></a>

### 3.1.11.4 Eligibility Criteria

<a id="topic-3.1.11.4-1"></a>

#### Key inclusion and exclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Inclusion, all participants | “Body mass index between 18.0 and 40.0 kg/m2” |
| Inclusion, renal impairment | “Diagnosis of chronic, stable renal function in the 6 months prior to dosing, as determined by the investigator, based on medical history or eGFR, and not requiring dialysis” |
| Exclusion, all participants | “History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair are allowed).” |
| Exclusion, normal renal function | “-Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator or designee.” |
| Exclusion, renal impairment | “History of any uncontrolled or unstable hepatic, hematological, gastrointestinal, neurological, endocrine, or psychiatric disorder, as determined by the investigator or designee, within 6 months prior to screening.” |
| Ages eligible for study | “18 Years to 75 Years (Adult, Older Adult )” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “Yes” |

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="heading-3.1.11.5"></a>

### 3.1.11.5 Treatment

<a id="topic-3.1.11.5-1"></a>

#### Arms and interventions in the ClinicalTrials.gov record

| Arm | Arm description |
| --- | --- |
| “Experimental: Healthy Volunteer” | “Up to 24 healthy volunteer participants will receive a single dose of ESK-001” |
| “Experimental: Mild Renal Impairment” | “8 participants with mild renal impairment will receive a single dose of ESK-001” |
| “Experimental: Moderate Renal Impairment” | “8 participants with moderate renal impairment will receive a single dose of ESK-001” |
| “Experimental: Severe Renal Impairment” | “8 participants with severe Renal impairment will receive a single dose of ESK-001” |

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="heading-3.1.11.6"></a>

### 3.1.11.6 Study Outcomes

<a id="heading-3.1.11.6.1"></a>

#### 3.1.11.6.1 Rationale for Using Pharmacokinetic Parameters and Adverse Event Incidence as the Primary Endpoints

<a id="topic-3.1.11.6.1-1"></a>

##### Primary and secondary outcome measures in the ClinicalTrials.gov record

| Role | Outcome measure | Time frame |
| --- | --- | --- |
| Primary | “Maximum observed plasma concentration (Cmax)” | “48 hours” |
| Primary | “Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation” | “48 hours” |
| Primary | “Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]” | “48 hours” |
| Primary | “Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]” | “48 hours” |
| Secondary | “Number of clinically significant changes in clinical laboratory values, vital signs, ECGs, and physical examinations” | “48 hours” |

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="heading-3.1.11.7"></a>

### 3.1.11.7 Statistical Analysis Description

<a id="heading-3.1.11.7.1"></a>

#### 3.1.11.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.11.7.1-1"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 16”

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="topic-3.1.11.7.1-2"></a>

##### Enrollment estimated at registration, April 2025, superseded in December 2025

> “Enrollment 48 [Estimated]”

Source: [ClinicalTrials.gov NCT06962774 version 1](https://clinicaltrials.gov/study/NCT06962774?tab=history&a=1)

<a id="heading-3.1.11.7.2"></a>

#### 3.1.11.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.11.8"></a>

### 3.1.11.8 Results

<a id="heading-3.1.11.8.1"></a>

#### 3.1.11.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.11.8.2"></a>

#### 3.1.11.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.11.8.3"></a>

#### 3.1.11.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.11.8.4"></a>

#### 3.1.11.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.11.8.5"></a>

#### 3.1.11.8.5 Safety Results

No evidence found.

<a id="heading-3.1.11.9"></a>

### 3.1.11.9 Study Limitations

<a id="topic-3.1.11.9-1"></a>

#### Summary

- No pharmacokinetic or adverse event results of the renal impairment study have been posted, and the report holds no published results; its ClinicalTrials.gov record reads “No Results Posted”.
- Only participants were masked, allocation was non-randomized, and each participant received a single dose with outcomes assessed over 48 hours.
- Enrollment was 16 participants, against 48 estimated at registration, at four sites in Florida; the record plans 8 participants each with mild, moderate, and severe renal impairment but does not report how many were enrolled in each group, and participants requiring dialysis were not eligible.

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774); [ClinicalTrials.gov NCT06962774 version 1](https://clinicaltrials.gov/study/NCT06962774?tab=history&a=1)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
